Pharvaris N.V. (PHVS)

NASDAQ: PHVS · IEX Real-Time Price · USD
27.32
-0.46 (-1.66%)
Feb 23, 2024, 4:30 PM EST - Market closed
-1.66%
Market Cap 1.42B
Revenue (ttm) n/a
Net Income (ttm) -114.17M
Shares Out 52.11M
EPS (ttm) -3.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,537
Open 28.17
Previous Close 27.78
Day's Range 27.27 - 28.43
52-Week Range 6.02 - 33.00
Beta -3.02
Analysts Buy
Price Target 28.00 (+2.49%)
Earnings Date Apr 3, 2024

About PHVS

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 65
Stock Exchange NASDAQ
Ticker Symbol PHVS
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for PHVS stock is "Buy." The 12-month stock price forecast is $28.0, which is an increase of 2.49% from the latest price.

Price Target
$28.0
(2.49% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacks Antagonism of the bradykinin B2 receptor via treatment ...

3 days ago - GlobeNewsWire

Pharvaris Announces Extraordinary Meeting of Shareholders

ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioe...

9 days ago - GlobeNewsWire

Pharvaris to Present at the WSAAI Annual Meeting 2024

ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioed...

4 weeks ago - GlobeNewsWire

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

ZUG, Switzerland, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioed...

4 weeks ago - GlobeNewsWire

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

ZUG, Switzerland, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioed...

7 weeks ago - GlobeNewsWire

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

ZUG, Switzerland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioed...

2 months ago - GlobeNewsWire

Pharvaris shares surge as treatment for severe swelling meets clinical trial goal

Shares of Pharvaris N.V. PHVS, +14.98% jumped 40% premarket on Wednesday after the Switzerland-based company said an investigational drug met its primary goal in a clinical trial for treatment and pre...

2 months ago - Market Watch

Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants

ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”, Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent ...

2 months ago - GlobeNewsWire

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioed...

2 months ago - GlobeNewsWire

Pharvaris to Present at the GA²LEN UCARE Conference 2023

ZUG, Switzerland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioed...

3 months ago - GlobeNewsWire

Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioed...

3 months ago - GlobeNewsWire

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

ZUG, Switzerland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioed...

3 months ago - GlobeNewsWire

Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update

ZUG, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioed...

4 months ago - GlobeNewsWire

Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting

ZUG, Switzerland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioed...

4 months ago - GlobeNewsWire

Pharvaris To Present at the APAAACI 2023 International Conference

ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioed...

4 months ago - GlobeNewsWire

Pharvaris To Present at the CIIC Fall 2023 Conference

ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioed...

5 months ago - GlobeNewsWire

Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference

ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioe...

5 months ago - GlobeNewsWire

Pharvaris To Present at the 18th German Allergy Congress

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioe...

6 months ago - GlobeNewsWire

Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioe...

6 months ago - GlobeNewsWire

Pharvaris To Present at the 2023 HAEi Regional Conference EMEA

ZUG, Switzerland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioed...

6 months ago - GlobeNewsWire

Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update

ZUG, Switzerland, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioed...

7 months ago - GlobeNewsWire

Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit

ZUG, Switzerland, July 21, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioed...

7 months ago - GlobeNewsWire

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

ZUG, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioed...

8 months ago - GlobeNewsWire

Pharvaris Announces $70 Million Private Placement Financing

ZUG, Switzerland, June 20, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists...

8 months ago - GlobeNewsWire

Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

ZUG, Switzerland, June 11, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioed...

9 months ago - GlobeNewsWire